STAT+: Pharmalittle: We’re reading about Amylyx pulling its ALS drug, GLP-1 drugs for Parkinson’s, and more
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease.
Top of the morning to you, and a fine one it is. After two days of downpours and strong winds, the Pharmalot campus is now enveloped by sunny skies and pleasant breezes, which is very
